• info@reportsandmarkets.com
  • +44-020-3286-9338 (UK) +1-214-377-1121 (US)
  • Sign In
  • Register

Pharmaceuticals & HealthcareRetinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Pipeline Review, H2 2018

  • RnM2315585
  • |
  • 7 August, 2018
  • |
  • Global
  • |
  • 73 pages
  • |
  • Global Markets Direct
  • |
  • Pharmaceuticals & Healthcare

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Pipeline Review, H2 2018

Summary

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Retinoic acid receptor beta (RARB) is a nuclear receptor that is encoded by the RARB gene. RARB bind as heterodimers to the target response elements in response to their ligands (all-trans or 9-cis retinoic acid) and gene expression in various biological processes. In the absence or presence of hormone ligand, acts mainly as anregulate activator of gene expression due to weak binding to co-repressors. It is required for skeletal growth, matrix homeostasis and growth plate functions.

Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Preclinical and Discovery stages are 2, 1, 3, 6, 4 and 1 respectively.

Similarly, the universities portfolio in Phase I stages comprises 1 molecules, respectively. Report covers products from therapy areas Dermatology, Gastrointestinal, Immunology, Respiratory, Central Nervous System, Hematological Disorders, Metabolic Disorders, Oncology and Ophthalmology which include indications Acne Vulgaris, Bronchopulmonary Dysplasia, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Promyelocytic Leukemia, Breast Cancer, Germ Cell Tumors, Hyperlipidemia, Inflammatory Bowel Disease, Myelodysplastic Syndrome, Neuroblastoma, Neutropenia, Non Alcoholic Fatty Liver Disease (NAFLD), Non-Alcoholic Steatohepatitis (NASH), Plaque Psoriasis (Psoriasis Vulgaris), Psoriasis, Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia, Retinopathy Of Prematurity, Sarcomas, Spinal Cord Injury, Traumatic Nerve Injury and Type 2 Diabetes.

The latest report Retinoic Acid Receptor Beta - Pipeline Review, H2 2018, outlays comprehensive information on the Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics development with respective active and dormant or discontinued projects.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB)
- The report reviews Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics and enlists all their major and minor projects
- The report assesses Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Overview
Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Companies Involved in Therapeutics Development
3SBio Inc
Bausch Health Companies Inc
Lee's Pharmaceutical Holdings Ltd
Phosphagenics Ltd
Promius Pharma LLC
Sol-Gel Technologies Ltd
Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Drug Profiles
(adapalene + benzoyl peroxide + clindamycin phosphate) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(adapalene + clindamycin hydrochloride) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(benzoyl peroxide + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(benzoyl peroxide + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(clindamycin phosphate + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(halobetasol propionate + tazarotene) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(TPX-6001 + tretinoin) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AC-261066 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
alitretinoin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KCL-286 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SBD-073 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tamibarotene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tazarotene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tazarotene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tretinoin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tretinoin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tretinoin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vitamin A palmitate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
vitamin A palmitate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Dormant Products
Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Discontinued Products
Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Product Development Milestones
Featured News & Press Releases
Jul 10, 2018: Syros to Host Key Opinion Leader Symposium on Acute Myeloid Leukemia and Myelodysplastic Syndrome on July 17, 2018
Jun 18, 2018: FDA declines to approve Valeant’s plaque psoriasis lotion
Jun 18, 2018: FDA Issues Complete Response Letter For DUOBRII (Halobetasol Propionate and Tazarotene) Lotion
Apr 09, 2018: Ortho Dermatologics Announces Publication of Pivotal Efficacy And Safety Data For Psoriasis Treatment DUOBRII In The Journal of the American Academy of Dermatology
Feb 15, 2018: Sol-Gel’s Phase 2 Data on TWIN to be Presented at the 2018 American Academy of Dermatology Annual Meeting
Jan 22, 2018: Syros Announces Issuance of U.S. Patents Covering Methods for Stratifying Patients for Treatment with SY-1425, Its First-in-Class Selective RARa Agonist
Jan 12, 2018: Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-121 Acne Treatment In Lotion Form
Jan 02, 2018: Syros Announces Clinical Supply Agreement with Janssen to Evaluate SY-1425, Its First-in-Class Selective RARa Agonist, in Combination with Daratumumab in Genomically Defined AML and MDS Patients
Dec 10, 2017: Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients
Nov 09, 2017: Promius Pharma Initiates Phase 3 Clinical Trials of DFD-03 for The Treatment of Acne Vulgaris
Nov 02, 2017: Ortho Dermatologics Announces U.S. FDA Filing Acceptance For IDP-118, Novel Plaque Psoriasis Treatment
Nov 01, 2017: Syros to Present Initial Clinical Data from Ongoing Phase 2 Clinical Trial of SY-1425 At ASH Annual Meeting
Oct 05, 2017: Syros Presents Biomarker Data from Its Ongoing Phase 2 Clinical Trial of SY-1425 in Genomically Defined AML and MDS Patients at ESH Conference on AML
Sep 29, 2017: Syros to Present Biomarker Data from Ongoing Phase 2 Clinical Trial of SY-1425 at ESH Conference on AML
Sep 28, 2017: A novel RARb agonist for spinal cord injury receives funding for a phase 1 trial from the MRC-DPFS
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer


captcha
Enter the code in the box:


captcha
Enter the code in the box:

Single User License (PDF)

  • This license allows for use of a publication by one person.
  • This person may not print out a single copy of the publication.
  • This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • This person cannot share the publication (or any information contained therein) with any other person or persons.
  • Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Site License (PDF)*

  • This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
  • These users may print out a single copy of the publication.
  • These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
  • These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
  • Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
  • Customers who infringe these license terms are liable for a Global license fee.

 

Global License (PDF)*

  • This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
  • Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
  • These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.


captcha
Enter the code in the box:



Summary:
Get latest Market Research Reports on Retinoic Acid Receptor Beta . Industry analysis & Market Report on Retinoic Acid Receptor Beta is a syndicated market report, published as Retinoic Acid Receptor Beta (RAR Beta or HBV Activated Protein or Nuclear Receptor Subfamily 1 Group B Member 2 or RAR Epsilon or NR1B2 or RARB) - Pipeline Review, H2 2018. It is complete Research Study and Industry Analysis of Retinoic Acid Receptor Beta market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


REPORT YOU MIGHT BE INTERESTED

Purchase this Report

$3,500.00
$7,000.00
$10,500.00
2,350.25
4,700.50
7,050.75
3,220.70
6,441.40
9,662.10
423,990.00
847,980.00
1,271,970.00
232,096.90
464,193.80
696,290.70
Add To Cart Credit card Logo

Related Reports


Reason to Buy